Showing 21 - 40 results of 130 for search '"Oligonucleotide"', query time: 0.07s Refine Results
  1. 21
  2. 22

    Classification, Mechanisms of Action, and Therapeutic Applications of Inhibitory Oligonucleotides for Toll-Like Receptors (TLR) 7 and 9 by Petar S. Lenert

    Published 2010-01-01
    “…In this review, we describe recent achievements in the development of oligonucleotide—(ODN)-based inhibitors of TLR9 and/or TLR7 signaling. …”
    Get full text
    Article
  3. 23

    Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: A Perspective by Stephanie A. Fernandes, Andrew G. L. Douglas, Miguel A. Varela, Matthew J. A. Wood, Yoshitsugu Aoki

    Published 2013-01-01
    “…Here, we discuss potential mechanisms and challenges for developing oligonucleotide-based therapy for c9FTD/ALS.…”
    Get full text
    Article
  4. 24
  5. 25
  6. 26
  7. 27
  8. 28
  9. 29
  10. 30
  11. 31
  12. 32
  13. 33
  14. 34
  15. 35
  16. 36
  17. 37

    Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer by Heather Lin, Vivek Subbiah, Siqing Fu, Aung Naing, Courtney Nicholas, Shubham Pant, Chad Tang, Michael A Curran, David S Hong, Ying Yuan, Sarina A Piha-Paul, Jordi Rodon Ahnert, Timonthy A Yap, Apostolia M Tsimberidou, Daniel D Karp, Anupallavi Srinivasamani, Coline Couillault, Genevieve P Hartley, James Dai, Ecaterina E Ileana Dumbrava, Paola Guerrero, Sarah Dhebat, Theresa Proia

    Published 2024-07-01
    “…Objective To evaluate signal transducer and activator of transcription 3 (STAT3) inhibition we conducted a co-clinical trial testing danvatirsen, a STAT3 antisense oligonucleotide (ASO) and checkpoint inhibition in conjunction with preclinical experiments.Methods and analysis Orthotopically implanted pancreatic cancer (pancreatic adenocarcinoma (PDAC)) was treated with STAT3 ASO with immune checkpoint inhibition. …”
    Get full text
    Article
  18. 38
  19. 39
  20. 40